Newsfeeds Archive - Spark Newswire

1 minute read

June 3, 7:38 AM

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that the primary study results from its CAHtalyst™ Pediatric Phase 3 study investigating crinecerfont for the treatment of congenital adrenal

NBIX

4 minute read

Analyst Ratings

Key Takeaways From Neurocrine Biosciences Analyst Ratings

By Benzinga Insights

May 28, 9:01 AM

16 analysts have expressed a variety of opinions on Neurocrine Biosciences (NASDAQ:NBIX) over the past quarter, offering a…

NBIX

1 minute read

Neurocrine Biosciences Phase 3 KINECT-4 Post Hoc Analysis Demonstrates Clinically Meaningful And Sustained Improvement In Tardive Dyskinesia With Long-Term Use Of INGREZZA Capsules

By Benzinga Newsdesk

May 21, 4:14 PM

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the publication of data from a post hoc analysis of the Phase 3 KINECT®-4 study of INGREZZA&r

NBIX

1 minute read

Neurocrine Biosciences Presents Data At ECE 2024, The CAHtalyst Program In Congenital Adrenal Hyperplasia And Study Data For Modified-Release Hydrocortisone In Primary Adrenal Insufficiency And CAH

By Benzinga Newsdesk

May 14, 8:43 AM

- CAHtalyst™ Phase 3 Baseline Characteristics Highlight Limitations of Current CAH Treatment Paradigm in Children, Adolescents and Adults- Phase 2 Study for Modified-Release Hydrocortisone in Adults with Adrenal

NBIX

1 minute read

Neurocrine Biosciences To Begin Initiation Of Phase 1 Clinical Study Evaluating Effects Of NBI-1117567 In Healthy Adults

By Benzinga Newsdesk

May 8, 8:38 AM

Neurocrine Biosciences, Inc. (NASDAQ:NBIX), today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational

NBIX

2 minute read

Neurocrine Biosciences To Present Phase 3 Baseline Characteristics Data From The CAHtalyst Program Of Crinecerfont In CAH, And Data For Modified-Release Hydrocortisone In Primary Adrenal Insufficiency And CAH Studies At ECE 2024

By Benzinga Newsdesk

May 7, 8:38 AM

CAHtalyst™ Pediatric and CAHtalyst™ Adult Baseline Characteristics Data in Congenital Adrenal HyperplasiaPhase 2 (CHAMPAIN) Clinical Study Data for Modified-Release Hydrocortisone

NBIX

3 minute read

Analyst Ratings

Cracking The Code: Understanding Analyst Reviews For Neurocrine Biosciences

By Benzinga Insights

May 1, 1:00 PM

In the latest quarter, 11 analysts provided ratings for Neurocrine Biosciences (NASDAQ:NBIX), showcasing a mix of bullish and…

NBIX

2 minute read

Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder

By Vandana Singh

April 23, 1:28 PM

Neurocrine Biosciences reports Phase 2 data for NBI-1065845 in major depressive disorder. Results show significant improvement in MADRS scores. William Blair sees the potential for $1 billion+ in sales.

NBIX

3 minute read

Analyst Ratings

Where Neurocrine Biosciences Stands With Analysts

By Benzinga Insights

April 10, 11:00 AM

Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on Neurocrine Biosciences…

NBIX

1 minute read

Neurocrine Biosciences Announces Initiation Of Phase 1 Clinical Study Evaluating Effects Of NBI-1065890, A Second-Generation VMAT2 Inhibitor, In Healthy Adults

By Benzinga Newsdesk

March 28, 8:34 AM

Neurocrine Biosciences, Inc. (NASDAQ:NBIX), today announced the initiation of its Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound

NBIX

Latest news

Neurocrine Biosciences’ Crinecerfont Shows Results in Pediatric CAH Study

Key Takeaways From Neurocrine Biosciences Analyst Ratings

Neurocrine Biosciences Phase 3 KINECT-4 Post Hoc Analysis Demonstrates Clinically Meaningful And Sustained Improvement In Tardive Dyskinesia With Long-Term Use Of INGREZZA Capsules

Neurocrine Biosciences Presents Data At ECE 2024, The CAHtalyst Program In Congenital Adrenal Hyperplasia And Study Data For Modified-Release Hydrocortisone In Primary Adrenal Insufficiency And CAH

Neurocrine Biosciences To Begin Initiation Of Phase 1 Clinical Study Evaluating Effects Of NBI-1117567 In Healthy Adults

Neurocrine Biosciences To Present Phase 3 Baseline Characteristics Data From The CAHtalyst Program Of Crinecerfont In CAH, And Data For Modified-Release Hydrocortisone In Primary Adrenal Insufficiency And CAH Studies At ECE 2024

Cracking The Code: Understanding Analyst Reviews For Neurocrine Biosciences

Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder

Where Neurocrine Biosciences Stands With Analysts

Neurocrine Biosciences Announces Initiation Of Phase 1 Clinical Study Evaluating Effects Of NBI-1065890, A Second-Generation VMAT2 Inhibitor, In Healthy Adults